Novartis AG Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (51)

Latest Posts

About This Stock More About This Stock
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
Article By: Zacks Investment Research
Friday, August 4, 2017 7:38 AM EDT
Shares declined 24% on Thursday, hitting a 52-week low of $23.33 per share. In fact, shares have slumped 34.5% so far this year compared with the industry’s decline of 1.9%.
In this article: TEVA, NVS, AGN, MYL
Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure
Article By: Zacks Investment Research
Tuesday, July 18, 2017 10:40 AM EDT
Novartis AG reported second-quarter 2017 core earnings of $1.22 per share.
In this article: NVS Also: JNJ, RHHBY, AMGN
Global Markets End On A Positive Note
Article By: Equitymaster India
Saturday, July 15, 2017 12:30 PM EDT
Global financial markets ended the week on a positive note with an upward boost from Brazil, Hong Kong and Indian share markets, which were up 5%, 4.1% and 2.1% respectively.
In this article: NVS
Sensex Opens Marginally Down; TCS Results Disappoint
Article By: Equitymaster India
Friday, July 14, 2017 1:00 AM EDT
Share markets in India have opened the day on a flat note with a negative bias. The BSE Sensex is trading lower by 31 points while the NSE Nifty is trading lower by 8 points.
In this article: NVS, EPI, INDA
Monday, Monday
Article By: Marvin R Clark
Tuesday, June 13, 2017 1:08 AM EDT
The Dow Industrials fell from record highs, with an inside trading session that does not look like a reversal, not yet anyway. The Nasdaq Composite confirmed its sharp downturn on Friday.
In this article: GE, AAPL, MSFT, FXB, GOOGL, NVS, AMGN


Latest Tweets for $NVS

No tweets yet!


Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Terry Chrisomalis 5/1/2017 12:22:24 AM

Yes it does indeed. #Novartis has been doing very well lately. $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Danielle Rogers 4/30/2017 5:29:49 PM

Triple the effectiveness over a placebo looks very promising! $NVS

1 to 3 of 3 comments